AMAG snags Cord Blood Registry for $700M

AMAG Pharmaceuticals has stepped in to buy Cord Blood Registry for $700 million, capturing about half of the privately stored cord blood units and taking a prominent position as supplier of stem cells to R&D groups. As Bloomberg notes, this deal further beefs up Waltham, MA-based AMAG's position in the maternal health field, following last November's acquisition of the maternal health unit of Lumara Health. Story

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.